| abstract |
The present invention relates to human antibodies that specifically inhibit VEGF, which binds only one of two major VEGF receptors (VEGFR2). The antibodies effectively inhibit neovascularization and induce tumor degeneration and have improved stability because of their specificity. The present invention therefore provides compositions, methods and combined protocols based on new human antibodies for treating cancer and other neovascular diseases. Advantageous immunoconjugate compositions and methods using novel VEGF-specific human antibodies are also provided. |